For citations:
Nedogoda S.V., Salasyuk A.S., Barykina I.N., Lutova V.O., Popova E.A. Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2026;1(19):16-23. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.357
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 